Page 920«..1020..919920921922..930940..»

mHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study – DocWire…

Posted: August 25, 2020 at 4:54 am

This article was originally published here

BMJ Open. 2020 Aug 20;10(8):e034723. doi: 10.1136/bmjopen-2019-034723.

ABSTRACT

INTRODUCTION: Depression and diabetes are highly disabling diseases with a high prevalence and high rate of comorbidity, particularly in low-income ethnic minority patients. Though comorbidity increases the risk of adverse outcomes and mortality, most clinical interventions target these diseases separately. Increasing physical activity might be effective to simultaneously lower depressive symptoms and improve glycaemic control. Self-management apps are a cost-effective, scalable and easy access treatment to increase physical activity. However, cutting-edge technological applications often do not reach vulnerable populations and are not tailored to an individuals behaviour and characteristics. Tailoring of interventions using machine learning methods likely increases the effectiveness of the intervention.

METHODS AND ANALYSIS: In a three-arm randomised controlled trial, we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen from different messaging banks by a reinforcement learning algorithm. The uniform random intervention group receives the same messages, but chosen from the messaging banks with equal probabilities. The control group receives a weekly mood message. We aim to recruit 276 adults from primary care clinics aged 18-75 years who have been diagnosed with current diabetes and show elevated depressive symptoms (Patient Health Questionnaire depression scale-8 (PHQ-8) >5). We will compare passively collected daily step counts, self-report PHQ-8 and most recent haemoglobin A1c from medical records at baseline and at intervention completion at 6-month follow-up.

ETHICS AND DISSEMINATION: The Institutional Review Board at the University of California San Francisco approved this study (IRB: 17-22608). We plan to submit manuscripts describing our user-designed methods and testing of the adaptive learning algorithm and will submit the results of the trial for publication in peer-reviewed journals and presentations at (inter)-national scientific meetings.

TRIAL REGISTRATION NUMBER: NCT03490253; pre-results.

PMID:32819981 | DOI:10.1136/bmjopen-2019-034723

Continued here:
mHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study - DocWire...

Posted in Diabetes | Comments Off on mHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study – DocWire…

Diabetes Prevention in the COVID-19 Era – Medscape

Posted: August 25, 2020 at 4:54 am

This transcript has been edited for clarity.

Hello, my name is Kamlesh Khunti. I'm professor of primary care diabetes and vascular medicine at the University of Leicester.

Thank you for joining me on this video regarding prevention of diabetes.

As you all know the prevalence of type 2 diabetes is a serious threat to sustainability of health systems internationally. But there is good quality evidence from randomised controlled trials that behavioural interventions that support people who are at high risk, such as those with impaired glucose tolerance (IGT), to lose weight, or to develop a healthy dietary lifestyle, and increasing physical activity, can reduce the risk of type 2 diabetes.

There've been a number of studies, including systematic reviews, that have shown that it doesn't matter which country the study has come from, the risk reduction is about 50% in those people who are at high risk and given intensive lifestyle interventions to prevent diabetes.

There are differences in terms of the risk reductions because the progression rates by IFG and IGT combined, IGT or IFT on its own, or HbA1c, are slightly different. But no matter what the criteria used to diagnose diabetes, we know that all these intensive lifestyle interventions can lead to weight loss, and which would subsequently lead to prevention of diabetes.

Evidence

The longest running study is the Da Qing study, which showed that at 6 years there was a 50% reduction in risk of developing diabetes in those with the IGT. And the 20 year follow up showed that there was still a 43% reduction in the incidence of developing type 2 diabetes. These were all efficacy trials where the participants had volunteered to go into a trial, and they had very, very intensive lifestyle interventions, which are not really applicable, or even sustainable, in a real-world setting.

So there's been a number of what we call effectiveness studies that have been conducted to reduce the incidence of diabetes and those at high risk. And again, a number of studies have been carried out what we call translational studies - and all of them have showed that we can improve risk factors in terms of developing diabetes.

And also, some studies, meta analyses, are showing that we can reduce the risk of diabetes in a real- world setting, and more data, even more data, for reductions in weight.

Guidelines

So on the basis of this a number of guidelines have been published. In the UK we have the National Institute for Health and Care Excellence (NICE) guidelines for England, which have said that we should be using some form of a risk score to identify those people who are at high risk.

And then those who are high on the risk score would have a blood test to see if they're high in terms of the blood test, and this could be a fasting glucose, or glucose tolerance test, or HbA1c.

Since the HbA1c criteria have come out, the majority of people are opting for an HbA1c. And people with an HbA1c of anything from 6% to 6.4% would be classed as being at high risk of diabetes, and they would be appropriately referred to a national Diabetes Prevention Programme. That started in England many years ago.

And this has led to a number of benefits over the years which I'll come to shortly.

In terms of the NICE guidance, NICE guidance showed that it was cost effective to identify people using the two-step approach where one would use a risk score and then refer patients to a diabetes prevention programme.

And indeed, they showed that in certain populations, such as those of ethnic minority populations, not just referring patients from age 40 to 74 as is the case in England, but referring patients from 25 to 39 of Black and Minority Ethnic (BAME) health groups would not only be cost effective, but also cost saving as well.

Recently, there's been a publication of the national programme. England has had the only national programme for diabetes prevention, and this showed that by December 2018 over 150,000 people have been referred and attended the initial assessment, of which 96,000 have attended at least one of the 13 group-based intervention sessions.

And intention to treat analysis within this observational study showed there was a 2.3 kg reduction in weight, and a 1.26 mmol/mol reduction in HbA1c. In terms of complete case analysis, there was about a 3.3 kg reduction in weight.

COVID-19

However, in view of COVID there's been a lot of debate - what should we be doing in terms of the prevention programme? Because first of all, it's been difficult to see these patients in clinical practice to have their blood tests done, HbA1c, for example, and then having the face-to-face group face education programmes.

Diabetes has really been heightened in the era of COVID because we know diabetes is one of the strong risk factors for severe COVID and hospitalisation. There's been a number of meta-analyses that have been done, all of them showing that people with diabetes have a two-fold increased risk of being hospitalised with COVID, and a two-fold increased risk of dying from COVID as well.

There's also now some good quality data showing that glycaemic control is associated with severe COVID and mortality. So, well-controlled people have a lower risk of mortality in those people who have diabetes. Whether the risk in people with pre-diabetes holds, we are still awaiting some results.

However, glucose does seem to be a risk factor for people with COVID and severe COVID.

So, our inclination would be to try and prevent diabetes. Also, physical fitness is important, so losing weight would be also beneficial in terms of contracting COVID and the risk associated with COVID.

In view of COVID, those people at high risk are now being given advice that they can have a risk score done. This is the Leicester Diabetes Risk Score, that is an online risk score available on the Diabetes UK website. Patients can assess their risk and those who are at high risk can enrol themselves to a risk reduction programme, the diabetes prevention programme, which is again an online programme.

This is a major announcement that was made by Sir Simon Stephens [NHS England chief executive], that the programme was now rolled out, all virtually, both in terms of risk assessment and for the prevention programme.

Unprecedented Times

This is exciting times, worrying times, but at the same time exciting times, because we do now work in an era of virtual consultations, and now also virtual programmes.

And we know that there are a number of digital support programmes globally that can be available, including wearable technologies. In the longer term, we will need to see if these programmes are effective, but we are working in unprecedented times.

We know diabetes is a risk factor for COVID severity and mortality, and whether people with diabetes in the pre-diabetes range are at high risk is to be asserted. But current data are showing that hyperglycaemia is a risk factor, and we need to continue all the efforts to reduce the risk of people developing diabetes, and hopefully reduce their risk of getting COVID, and severe outcomes from COVID.

Thank you very much for listening.

Here is the original post:
Diabetes Prevention in the COVID-19 Era - Medscape

Posted in Diabetes | Comments Off on Diabetes Prevention in the COVID-19 Era – Medscape

Rapper Loses Leg to Diabetes and Friends Rally to Support – The Beet

Posted: August 25, 2020 at 4:54 am

When a famous rapper loses a leg to diabetes there is little to do but offer sympathy and give to the GoFundMe page set up for his treatment and follow up care. Today, as we listened to The Beet's Creative AdvisorJermaine Dupri being interviewedfor HipHopDX,we learned that Andre "Doctor Dre" Brown, most known for having starred in the MTV show Yo! MTV Raps with Ed Lover inthe late 80s to mid-90s, had his leg amputated earlier this summer, the result of complications from diabetes.

Doctor Dre not to be confused with the west coast producer, co-founder of Beats by Dre headphones and former member of NWA Dr. Dreis credited as having "exposedHip Hop to a whole new audience while introducing the genre into living rooms across the United States," according to a story in HipHopDX.

Doctor Dre made his mark in radio, television, movies and had worked as a DJ, composer, talent scout, program host, actor, critic, and author. But he is best known as co-host with Ed Lover of Yo! MTV Raps,"theTV show that did more than any other to make rap music and hip-hop culture global phenomena," according to ABCnews.com

From 1989 to 1995, Doctor Dr andEd Loverwere the co-hosts of Yo! MTV Raps. Dr had already teamed up with Lover in the early 1990s to co-host a morning radio show as part of the re-launch of Hot 97in New York City.

The pair starred in the1993filmWho's the Man?, directed byYo! MTV Rapsco-creator and co-directorTed Demme. Dr and Ed Lover also recorded an album in 1994 titledBack up off Me! Dr also served as a DJ for theBeastie Boys.Hehad his own clothing line calledBigga Stuffin the early 1990s. In 2003 Dr and Ed Lover participated in theComedy Central Roastof theirWho's the Man?co-star, comedianDenis Leary.

Dre also guest-starred onThe Fresh Prince of Bel-Airin the episode "Ill Will" as a figment ofWill Smith's nightmare of bad doctors. He then appeared on an episode ofThe People's Courtwith JudgeMarilyn Milianas a witness for a talent director suing former colleagues of his.

HisGoFundMe page reads:

Friends,

All of us who lived through the Nineties and care about music know and love Andre "Doctor Dre" Brown. He has made his mark on radio and television, in the movies and in print, working successively as a recording artist (as a founding member of Def Jam's Original Concept), hip-hop DJ (he was the Beastie Boys's DJ during the Raising Hell Tour in 1986) , composer, talent scout, on-air personality, actor, author, and critic. He's undoubtedly best-known as the co-host with Ed Lover of "Yo! MTV Raps" (1989-1995), the tv show that did more than any other to make rap music and hip-hop culture global phenomena. After "Yo!", Dre and Ed duo funneled their chemistry into major market radio. They held down the morning show on New York's Hot 97 (1993-1998), then on L.A.'s The Beat (2000-2001), and finally on New York's Power 105 (2003-2006).

Fans of Doctor Dre (whose real name is Andre Brown) is a big personality and well-loved in the Hip Hop community. He has suffered from type 2 diabetes for years, and when diabetes gets advanced it can cut off circulation to the capillaries that supply oxygen to the toes, eyes and other areas of the body that when damaged can not heal properly. One way to prevent and even reverse symptoms of type 2 diabetes is a plant-based diet, which lowers inflammation and helps keep blood sugar under control.

Even as recently as 10 months ago, he was trying to turn things around.Brownexplained that hes not completely blind, and has undergone retina reattachment surgery. The resulting scar tissue causes his vision to fluctuate. As a result, hes currently more focused on higher factors.

Im learning its better what you put in your mouth to help treat the situation, Brown said. But Ive learned to say I believe in a higher spirit, and he speaks to me all the time.

Now he is alsomostly blinddue to complications stemming from his condition. Back in 2016 when he was awaiting weight loss surgery to help him treat his condition, Doctor Dretold The New York Times:

My stubbornness put me where Im at. Now my energy is going to change that. We got young people, grown people, old, all having this. We can prevent this. We can cure this. I have an idea of how to do it.

Diet and lifestyle changes can help reverse and reduce symptoms of diabetes, as Eric Adams, Brooklyn Borough President, found out when he started to experience declining vision. He was overweight and in poor health until he switched to a vegan diet, lost 35 pounds and got healthier. He's recently written a book about his transformation, due out this fall, called Healthy at Last: A Plant-Based Approach to Preventing and Reversing Diabetes and Other Chronic Illnesses.

A new study just published this month found that a plant-based diet controls blood sugar and helps your body naturally metabolize carbs and fat, to help avoid diabetes. And another review study of diets showed that you reap the benefits of eating more plants when avoiding diabetes is the goal.Thisstudyfound that the more plants, the better.

Our thoughts and prayers are with Doctor Dre and his family. To contribute to his GoFundMe Page click here.

Read the rest here:
Rapper Loses Leg to Diabetes and Friends Rally to Support - The Beet

Posted in Diabetes | Comments Off on Rapper Loses Leg to Diabetes and Friends Rally to Support – The Beet

Chancellor Harold L. Martin, on His Plan to Safely Open the Nation’s Largest HCBU During COVID-19 – TIME

Posted: August 23, 2020 at 8:58 am

(Miss this weeks The Leadership Brief? This interview above was delivered to the inbox of Leadership Brief subscribers on Sunday morning, Aug. 23; to receive weekly emails of conversations with the worlds top CEOs and business decisionmakers, click here.)

Education has become as much about logistics as instruction during the COVID-19 crisis, and Harold L. Martin, the chancellor of North Carolina Agricultural and Technical State University, has spent the summer months immersed in planning to make returning to campus as safe as possible for the schools student body, faculty and staff. With more than 12,500 students, NC A&T is the nations largest historically black university and under Martin, it has become one of the top producers of African American STEM graduates in the country.

Demand for the schools STEM graduates has increased so much in recent years that the school has added multiple job fairs to handle the influx of recruiters from big tech companies.

Classes started Aug. 19 with a hybrid model. About 70% percent of students returned to the Greensboro campus for a combination of virtual and in-person instruction, in classrooms outfitted with plexiglass protections for professors and socially distanced seating. Football and other fall sports have been canceled. Martin, 68, joined TIME for a video conversation about the schools safety protocols, what its like to lead an institution with a rich history in the civil rights movement during a period of national protests against systemic racism (the Greensboro Four, who began the historic 1960 sit-in at the Woolworths lunch counter in Greensboro, were all freshmen at NC A&T and are known locally as the A&T Four), and the selection of Sen. Kamala Harris as the Democratic vice presidential candidate.

Subscribe to The Leadership Brief by clicking here.

This interview has been edited and condensed for clarity.

Senator Harris embodies so much that is important and worthy about historically black universities, and it is truly a historic moment to see one of our graduates included on the Democratic ticket. We join our friends at Howard in their celebration of this extraordinary development. Having experienced the history-making presidential campaigns of our own alumnus, the Rev. Jesse Jackson, in 1984 and 1988, we know well the national significance of such an electoral event and how it can help many Americans to see HBCUs in a new and perhaps different light.

Its the same argument I gave myself when we spoke to both our boys who are both overachievers academically: that we want you to go to a university where you will have access to the very best faculty and the best friends and the best experiences to grow personally and professionally. And never have compromised in any way, shape or fashion your preparation for your career or for your profession or for access to Americas top graduate and professional schools. We can demonstrate that time and time again, there are very few universities in America that do what we do as well as we do it for African American students.

HBCUs have fared well in federal funding over the past three years. Title III support has increased. $85 million in annual STEM funding for HBCUs was made permanent and year-round funding for Pell Grants was approved. Passage of all of those reflect positively on the president and his administration.

Well, Im insulted quite honestly. Im sort of appalled by the notion that one would make such a claim.

No.

I think he tends to inflame situations and tends to divide versus providing a voice that is healing for our nation on the heels of COVID-19 where theres been evidence of so many missteps by the Administration.

Probably as optimistic as Ive been. I do feel its in a different moment. The corporate boards I serve on, we have a very different conversation with our board members about what this means and how we must rethink the way we do business. I spend enormous amounts of my time engaging with our students, and I believe because of the great history and traditions of our university as an institution actively involved in social change over the decades, and because of my own experiences growing up in America, as an African American individual, overlapping into periods of segregation and Jim Crow, my experiences tell me this feels different. This is more than just about police brutality. This is also very significantly about disparities in America that are embedded in racism through education, health care, unemployment, wealth, et cetera. And no matter how you cut it, were not going to get out of some of these deep-seated race-based disparities until America comes to grip with our racism.

If I look at most people in America, those who have not come from wealth, education has played the biggest part in transforming those individuals lives, including my own. And as a consequence I would say that education is one of the most critical investments we can make in changing the outcomes and trajectory for young people in America.

If I look at most people in America, those who have not come from wealth, education has played the biggest part in transforming those individuals' lives, including my own.

It is a great point of pride for us. The number of corporations and agencies that have come to our university to recruit our graduates over the last five to seven years has grown in record numbers. We have built very strong relationships with Apple, Intel, Google, Facebook, Twitter, for example. Amazon. Silicon Valley recruits our graduates in record numbers, along with a host of organizations and state agencies and federal agencies from around the world.

Its a mixed bag. I believe certainly in the most recent few months following the unfortunate murder of George Floyd for all the world to see, theres a higher level of consciousness around having more meaningful conversations.

I shared this with my corporate colleagues and CEOs of these organizations. Look, you cant continue to come to the table and drop a dime here and a dollar there. Or multiple dollars there. Youre trying to get access to our very best resource, and we have to make big investments to make that happen.

We have seen significant increases in internship opportunities for our students. And weve seen significant increases in corporate contributions and foundation contributions.

Over the years, the military has been one of the leading organizations in America that has valued diversity. It has not all been perfect by any measure, but its been one of the leading organizations that has provided advancement opportunities for people of color. Our ROTC program has become an incredible source of pride for our university. It serves as the hub for all ROTC programs in the region. We attract exceptionally talented students who are engineers and health care providers who are graduating and theyre being commissioned at commencement. And theyre going off to serve America.

My PhD dissertation was a highly theoretical model representing computer systems that were framed as a mathematical model, and if they were interconnected in such a way that these interconnected computers would communicate like cells in the body. Whether I wanted to remain engaged in research and teaching graduates being engaged in scholarship, or be pulled away into administration, that was really a tug-of-war for me.

Guarded but comfortable.

All of our students who are returning to the campus have been checked for symptoms as they move into the residence hall .

We obviously are requiring masking. Safe social distancing. We have a high intensity cleansing protocol on a daily basis and a daily morning ritual of self-assessment, of all students who are living in residence halls. And each of our classrooms was reduced to about 30% occupancy.

They can apply to telework. Weve been very generous in providing those employees the opportunity to tele-work.

About 60% of our faculty will be tele-working this fall.

About 60% of our faculty will be tele-working this fall.

Weve ordered a million masks. And then weve ordered somewhere around 30 to 40,000 branded cloth masks. All students, faculty and staff will get at least two of those.

Our students are responding overall. They are 18, 19, 20 year olds, though, and so we have to continue to remind them of the expectations, quite honestly.

It is an inspiration to me. In every conversation , itll come up. We cant compromise what we do.

Subscribe to The Leadership Brief by clicking here.

BUSINESS BOOK: Good to Great by Jim Collins

AUTHOR: Isaac Asimov

APP: Twitter

EXERCISE/STRESS RELIEVER: Walking and working out in home gym. And golf, schedule permitting.

Subscribe to The Leadership Brief by clicking here.

For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Contact us at editors@time.com.

Go here to see the original:
Chancellor Harold L. Martin, on His Plan to Safely Open the Nation's Largest HCBU During COVID-19 - TIME

Posted in North Carolina Stem Cells | Comments Off on Chancellor Harold L. Martin, on His Plan to Safely Open the Nation’s Largest HCBU During COVID-19 – TIME

Inside the race to ditch formula and grow breast milk in the lab – Wired.co.uk

Posted: August 23, 2020 at 8:58 am

Like most expectant mothers, Stephanie King had a firm idea of how she wanted the birth of her children to go. But when the time came to have her twins in July 2019, her plans started unravelling.

Stanley, the first twin, was nearly born in the car park. He came so fast that I didnt even get to have gas and air, says King, who lives in Herefordshire in the UK. Soon after, the heartbeat of her second twin Sophia dropped so dramatically that the doctors sent King for an emergency caesarean section. Both babies were fine, but King wasnt. She haemorrhaged severely, losing five litres of blood. As if that wasnt enough, she then developed an antibiotic-resistant infection in her womb, which later spread to her blood and turned septic. Pneumonia followed and then her chest cavity filled with pus, requiring two further surgeries.

It would be eight long weeks before King returned home. On strong antibiotics and hormone replacement therapy, she couldnt safely breastfeed her twins. It was almost more traumatic than what I had been through in the hospital, says King, whose older son self-weaned at the age of three. Because I had breastfed my son for so long, I knew the nutritional benefits breast milk provides.

According to the World Health Organisation, breast milk is an important source of nutrients and energy for infants, protecting against gastrointestinal infections, and helping to reduce obesity risk while improving IQ later on in life, among other benefits. For mothers like King unable to breastfeed yet still wanting to provide their babies human milk the options are limited. Milk banks arent available in every country or city, and marketplaces on Facebook, Craigslist and other online platforms are poorly regulated.

Fengru Lin is trying to find a way around the problem. In January 2019, Lin founded TurtleTree Labs, a Singapore-based startup that is attempting to grow human breast milk in a laboratory. The company starts with stem cells taken from donor breast milk, multiplies them before putting them into a growth fluid within a hollow fibre bioreactor imagine a giant steel cup with hundreds and thousands of little perforated straws, says Lin. There, the cells differentiate into mammary ones and start producing milk. The entire process takes three weeks, says Lin, and the mammary cells can lactate for roughly 200 days.

Its a technique that can theoretically be used to obtain milk from any mammal, as long as stem cells are available. TurtleTree has already successfully produced full-composition cows milk from stem cells in freshly-expressed cow's milk. It now plans to do the same for human milk. Were not trying to replace breastfeeding, which is something were fully behind," says Lin, who was first drawn to the idea of making milk from cells because of a passion for cheesemaking.

More than 80 per cent of new mothers in the US and UK start out breastfeeding, but only half and a third, respectively, still do so exclusively at six months. Globally, this figure is 37 per cent. The reasons vary: some struggle to produce sufficient amounts, while others have to return to work where pumping and storing milk isnt convenient. Many also find expressing milk physically painful, experiencing mastitis, chafed nipples and other excruciating effects. Then there are mothers on medications or undergoing treatments that make it unsafe for them to breastfeed. And sometimes, babies may be premature or too weak to suckle. The fact is mums rely on infant formula, says Lin. Thats where we want to be the next best thing.

While formula has come a long way, especially in the past two decades, it still lacks many nutrients found in breast milk. And thats largely because most infant formulas are based on cow, rather than human, milk. The two contain mostly the same type of molecules but in different proportions, says Alan Kelly, a food scientist at University College Cork in Ireland. And the difference in those levels is very physiologically significant.

The mineral levels in cows milk are much higher and so is its protein content (3.5 versus one per cent), while the carbohydrates levels are significantly lower (roughly 4.5 versus seven per cent), he says. Crucially, there are a group of complex carbohydrates that are unique to human milk. Its now known that oligosaccharides play a huge role in the development of an infant, for example protecting against infections, says Kelly. Infant formula can be tweaked to adjust for some of these differences, but it cant fully replicate the real thing.

And because formula uses cows milk as a starting material, the environmental cost of producing it is also substantial. It takes an estimated 4,700 litres of water to make just one kilogram of milk powder. Formula also frequently contains palm oil, which has a large carbon footprint.

Lab-grown breast milk holds the potential to alleviate some of these problems. Some of it has to do with a renewed interest in sustainability, while the rest is because we now have a much deeper understanding of the different types of cellular agriculture, says Michelle Egger, co-founder of the North Carolina-based startup BioMilq, which is also looking to produce breast milk in the lab.

To everyone else, it sounds like pigs flying, she says. But for us, its just applying science in a way that can help more women.

While both Biomilq and TurtleTree Labs who have each raised more than $3.5 million (2.65m) in funding hope to eventually produce human milk sans breasts, there are some key differences. For one, Biomilq is working directly with mammary epithelial cells rather than stem cells. Its also aiming to sell milk directly to consumers, whereas TurtleTree plans to license its technology to large formula companies.

Any milk made in a lab wont be able to replicate the immune benefits that breastfeeding gives to infants. Human breast milk contains high amounts of antibodies produced in the blood that are then passed on to the baby, giving them some protection against diseases. Breast milk is an extraordinarily complex biofluid, says Natalie Shenker, a breast milk researcher at Imperial College London. Not only does it have hundreds of proteins and more than 200 oligosaccharides, it also comprises a multitude of hormones, fats and beneficial bacteria, which are made elsewhere in the body and transported into mammary cells.

These components which cannot be replicated in the lab are crucial for renal, cell membrane and immune system development, says Shenker. Plus they help keep fluid and electrolyte levels consistent, among other functions.

In addition, breast milk is a dynamic substance that responds to a babys changing needs. Saliva can flow backwards into the milk duct and be a way of signalling to the mother, says fellow breast milk researcher Maryanne Perrin at the University of North Carolina Greensboro. And some studies show that antimicrobial proteins go up with an infant illness.

Shenker adds: [Human milk] is tailored based on the mothers and babys genetics, the environment they live in, the geography, season and even temperature of the day thats how responsive human milk is.

Biological differences aside, a number of hurdles remain before lab-grown milk becomes a reality. For one, firms must find a way to keep the most costly aspects of production the nutrients and lactation media low in order for the milk to be affordable. Scaling up also comes with technical difficulties. TurtleTree Labs is currently optimising their lactation process in a five-litre bioreactor, which they hope to scale up linearly to industrial size ones of 1,000 and 50,000 litres next year. (Biomilq declined to share the size of its reactors.)

Figuring out how to preserve the final product will also be key, says Kelly. Pasteurisation, freezing or dehydrating it into a powder might change some of the milks components and undo some of its advantages.

Safety testing is another big hurdle that the companies will have to overcome. This is not just you and me going to the supermarket and buying food for ourselves, says Perrin. Infants are considered a vulnerable population. Its ethically tricky to conduct clinical trials when such young infants are involved. And because lab-grown breast milk is uncharted waters, regulatory authorities will have to figure out how to classify it and even create a formal breastmilk standard (which doesnt currently exist).

I think the research going into making breast milk in the lab is a wonderful prospect, says King, who was forced to rely on formula to feed her twins in the early weeks, but is now breastfeeding them exclusively. Had I been offered donor milk initially or if this lab-grown breast milk was in full swing, then that is what I would have gone for first.

Night trains are brilliant. So why doesnt the UK have any to Europe?

The race is on to create a vaccine. This mRNA coronavirus vaccine is two breakthroughs in one

Need some peace? These are the best noise-cancelling headphones in 2020

Listen to The WIRED Podcast, the week in science, technology and culture, delivered every Friday

Follow WIRED on Twitter, Instagram, Facebook and LinkedIn

Get The Email from WIRED, your no-nonsense briefing on all the biggest stories in technology, business and science. In your inbox every weekday at 12pm sharp.

by entering your email address, you agree to our privacy policy

Thank You. You have successfully subscribed to our newsletter. You will hear from us shortly.

Sorry, you have entered an invalid email. Please refresh and try again.

See more here:
Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk

Posted in North Carolina Stem Cells | Comments Off on Inside the race to ditch formula and grow breast milk in the lab – Wired.co.uk

Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of…

Posted: August 23, 2020 at 8:57 am

HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today its subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a specialist healthcare center focused on cell therapy and regenerative medicine. Executives from both companies took part in a signing ceremony held via video conference between Israel and the UAE. The aim of the collaboration is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole. The collaboration between the parties was initiated by the Better Alternatives advisory firm.

The parties have agreed to exchange research results, share samples, join usage of equipment and testing, and other essential activities related to advancing the treatment and research of cell therapies for a broad range of medical conditions, including COVID-19.

ADSCC has been treating COVID-19 patients with stem cells sourced from the patients blood, by returning the cells back into the patients lungs as a fine mist through a nebulizer, a machine that helps a patient breathe in medicine through a mask or mouthpiece. Pluristem has treated patients with its placental PLX-PAD allogenic product via compassionate use programs in Israel and the U.S. and is currently conducting phase II studies in the U.S. and EU.

We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders. We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world. I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. We are honored to be on the front line of this historical moment, stated Pluristem CEO and President Yaky Yanay.

Dr Yendry Ventura, General Manager of the ADSCC commented, Pluristem is a major player in the cell therapy field with years of experience, a unique platform and a robust clinical pipeline. We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole.

About Abu Dhabi Stem Cells CenterAbu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine, as well as delivering cutting-edge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. ADSCC specialties include immunology, hematology, clinical stem cell therapy, molecular biology, immunotherapy, orthopedics, and urology amongst others.

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the aim of the collaboration with the ADSCC is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole and the belief that it is its obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana RubinDirector of Investor Relations972-74-7107194danar@pluristem.com

View original post here:
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of...

Posted in Cell Medicine | Comments Off on Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of…

Nasal vaccine against COVID-19 prevents infection in mice – Washington University School of Medicine in St. Louis

Posted: August 23, 2020 at 8:57 am

Visit the News Hub

Nasal delivery produces more widespread immune response than intramuscular injection

Researchers at Washington University School of Medicine in St. Louis have developed a COVID-19 vaccine delivered via the nose that protects mice from the virus. Shown is mouse lung tissue infected with SARS-CoV-2, the virus that causes COVID-19. On the left is lung tissue from a mouse that received a control vaccine that produced no protective effects. It shows a large number of inflammatory cells. On the right is lung tissue from a mouse that received a nasal vaccine encoding the virus' spike protein. The vaccine protected against infection, and large numbers of inflammatory cells are absent.

Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus. The investigators next plan to test the vaccine in nonhuman primates and humans to see if it is safe and effective in preventing COVID-19 infection.

The study is available online in the journal Cell.

Unlike other COVID-19 vaccines in development, this one is delivered via the nose, often the initial site of infection. In the new study, the researchers found that the nasal delivery route created a strong immune response throughout the body, but it was particularly effective in the nose and respiratory tract, preventing the infection from taking hold in the body.

We were happily surprised to see a strong immune response in the cells of the inner lining of the nose and upper airway and a profound protection from infection with this virus, said senior author Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine and a professor of molecular microbiology, and of pathology and immunology. These mice were well protected from disease. And in some of the mice, we saw evidence of sterilizing immunity, where there is no sign of infection whatsoever after the mouse is challenged with the virus.

To develop the vaccine, the researchers inserted the virus spike protein, which coronavirus uses to invade cells, inside another virus called an adenovirus that causes the common cold. But the scientists tweaked the adenovirus, rendering it unable to cause illness. The harmless adenovirus carries the spike protein into the nose, enabling the body to mount an immune defense against the SARS-CoV-2 virus without becoming sick. In another innovation beyond nasal delivery, the new vaccine incorporates two mutations into the spike protein that stabilize it in a specific shape that is most conducive to forming antibodies against it.

Adenoviruses are the basis for many investigational vaccines for COVID-19 and other infectious diseases, such as Ebola virus and tuberculosis, and they have good safety and efficacy records, but not much research has been done with nasal delivery of these vaccines, said co-senior author David T. Curiel, MD, PhD, the Distinguished Professor of Radiation Oncology. All of the other adenovirus vaccines in development for COVID-19 are delivered by injection into the arm or thigh muscle. The nose is a novel route, so our results are surprising and promising. Its also important that a single dose produced such a robust immune response. Vaccines that require two doses for full protection are less effective because some people, for various reasons, never receive the second dose.

Although there is an influenza vaccine called FluMist that is delivered through the nose, it uses a weakened form of the live influenza virus and cant be administered to certain groups, including those whose immune systems are compromised by illnesses such as cancer, HIV and diabetes. In contrast, the new COVID-19 intranasal vaccine in this study does not use a live virus capable of replication, presumably making it safer.

The researchers compared this vaccine administered to the mice in two ways in the nose and through intramuscular injection. While the injection induced an immune response that prevented pneumonia, it did not prevent infection in the nose and lungs. Such a vaccine might reduce the severity of COVID-19, but it would not totally block infection or prevent infected individuals from spreading the virus. In contrast, the nasal delivery route prevented infection in both the upper and lower respiratory tract the nose and lungs suggesting that vaccinated individuals would not spread the virus or develop infections elsewhere in the body.

The researchers said the study is promising but cautioned that the vaccine so far has only been studied in mice.

We will soon begin a study to test this intranasal vaccine in nonhuman primates with a plan to move into human clinical trials as quickly as we can, Diamond said. Were optimistic, but this needs to continue going through the proper evaluation pipelines. In these mouse models, the vaccine is highly protective. Were looking forward to beginning the next round of studies and ultimately testing it in people to see if we can induce the type of protective immunity that we think not only will prevent infection but also curb pandemic transmission of this virus.

This work was supported by the National Institutes of Health (NIH), grant and contract numbers 75N93019C00062, R01 AI127828, R01 AI130591, R01 AI149644, R35 HL145242, HHSN272201400018C, HHSN272201200026C, F32 AI138392 and T32 AI007163; the Defense Advanced Research Project Agency, grant number HR001117S0019; a Helen Hay Whitney Foundation postdoctoral fellowship; and the Pulmonary Morphology Core at Washington University School of Medicine.

Diamond is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and on the scientific advisory board of Moderna. The Diamond laboratory has received unrelated funding support from Moderna, Vir Biotechnology, and Emergent BioSolutions. Diamond, Curiel, Ahmed Hassan and Igor Dmitriev have filed a disclosure with Washington University for possible development of ChAd-SARS-CoV-2. Michael Holtzman is a member of the DSMB for AstroZeneca and founder of NuPeak Therapeutics. The Baric laboratory has received unrelated funding support from Takeda, Pfizer and Eli Lily.

Hassan AO, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. Aug. 19, 2020.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more:
Nasal vaccine against COVID-19 prevents infection in mice - Washington University School of Medicine in St. Louis

Posted in Cell Medicine | Comments Off on Nasal vaccine against COVID-19 prevents infection in mice – Washington University School of Medicine in St. Louis

Impact of COVID 19-Global Stem Cell Exosome Therapeutic Market Research Report 2020: Evox Therapeutics, Capricor Therapeutics, Inc., Unicyte AG,…

Posted: August 23, 2020 at 8:57 am

InsightAce Analytic new report on Global Stem Cell Exosome Therapeutic market offers a detailed evaluation of the global industry by analysing market dynamic factors including the drivers, challenges and trends in upcoming years. Also, it includes the detailed analysis of local as well as international players involved in Global Stem Cell Exosome Therapeutic industry. These market dynamic factors are analyzed in the report to see an overall impact on the global market revenue forecast.

Global Stem Cell Exosome Therapeutic Market-Competitive Landscape:

Key players operating in the Stem Cell Exosome Therapeutic market include Evox Therapeutics, Capricor Therapeutics, Inc., Unicyte AG, Exogenus Therapeutics, Everkine Corporation, Creative Medical Technology Holdings, Anjarium Biosciences, Kimera Labs, ReNeuron, Stem Cell Medicine Ltd., and Codiak Biosciences

Request for Sample Pages: https://www.insightaceanalytic.com/report-details/global-stem-cell-exosome-therapeutic-market-assessment-research-report/#request-for-tocproposal

Global Stem Cell Exosome Therapeutic Market Report Overview:

The Report provide in-depth analysis and the efficient research material of the Global Stem Cell Exosome Therapeutic market. This new report on the Global Stem Cell Exosome Therapeutic Market is committed fulfilling the requirements of the clients by giving them thorough insights into the Global Stem Cell Exosome Therapeutic market. An exclusive data offered in this report is collected by research and industry experts.

The Global Stem Cell Exosome Therapeutic Market report covers scope and overview to define the key terms and offers detailed information about Global Stem Cell Exosome Therapeutic industry. This is followed by the regional outlook with revenue forecast and segmental analysis. The report also consists of the facts and key values of the Global Stem Cell Exosome Therapeutic Market in terms of volume, revenue and its growth rate. This report highlights a exhaustive list of companies involved in the market and gives details of their products, financials, operations, and business strategy.

The report includes a wealth of financial data and business strategy information such as sales & revenue figures, Revenue and unit shipment market forecasts, up-to-date company financials, business model strategies for companies involved in market and comprehensive account of company products, financials and portfolios.

Global Stem Cell Exosome Therapeutic market future growth rates and forecast projections are provided which offers a forthcoming perspective of Global Stem Cell Exosome Therapeutic growing industry. Current developments relating to Global Stem Cell Exosome Therapeutic products are discussed. The emerging trends that appear in key sub-markets are elucidated and analysed

Request for ToC/Proposal: https://www.insightaceanalytic.com/report-details/global-stem-cell-exosome-therapeutic-market-assessment-research-report/#request-for-tocproposal

Global Stem Cell Exosome Therapeutic Market Segmentation

Global Stem Cell Exosome Therapeutic Market by Application Type

Global Stem Cell Exosome Therapeutic Market: by Regional & Country Analysis

Key Benefits for Global Stem Cell Exosome Therapeutic Market Reports

Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/report-details/global-stem-cell-exosome-therapeutic-market-assessment-research-report/#request-for-tocproposal

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.Tel.: +1 718 593 4405Email:[emailprotected]Site Visit:www.insightaceanalytic.comFollow Us on LinkedIn @bit.ly/2tBXsgSFollow Us OnFacebook@bit.ly/2H9jnDZ

View original post here:
Impact of COVID 19-Global Stem Cell Exosome Therapeutic Market Research Report 2020: Evox Therapeutics, Capricor Therapeutics, Inc., Unicyte AG,...

Posted in Cell Medicine | Comments Off on Impact of COVID 19-Global Stem Cell Exosome Therapeutic Market Research Report 2020: Evox Therapeutics, Capricor Therapeutics, Inc., Unicyte AG,…

Treating COVID-19: Bipolar drug shows promise and other hopeful findings – Medical News Today

Posted: August 23, 2020 at 8:57 am

We continue our Hope Behind the Headlines series by exploring the most recent and most hopeful findings in the field of COVID-19 research.

Hopefully, the COVID-19 pandemic will not last forever. Every 2 weeks, we round up the recently published evidence that reminds us of this.

In our last installment, we reported on a vaccine candidate that showed promise in monkeys and a new trial that tested an existing drug, among other innovations.

In this feature, we discover another existing drug that could treat the infection. We also learn about T cells and how a new blood test could speed up vaccine development and mass screening.

Furthermore, we zoom in on a class of immune-modifying drugs that may be the most effective treatment for severe forms of the disease.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

Researchers have found that a drug that doctors currently use for treating conditions as varied as bipolar disorder and hearing loss also has antibacterial and anti-inflammatory properties. These properties make it a good candidate for treating COVID-19.

The drug is called Ebselen, and the fact that it is already in use indicates its safety. Furthermore, previous evidence has shown that Ebselen can block enzymes that the new coronavirus needs for replicating within healthy host cells.

This enzyme is called Mpro, and researchers have described this protease as indispensable for the replication of SARS-CoV-2. As a result, Mpro is an excellent drug candidate.

In the new study, Prof. Juan de Pablo, from the Pritzker School of Molecular Engineering at the University of Chicago, IL, and his colleagues set out to test whether Ebselen can indeed inhibit the Mpro protease.

To find out, they created computer models of both the drug and Mpro to see how they interact. They found that the drugs action is two-pronged:

In addition to binding at the catalytic site of the enzyme, Ebselen also binds strongly to a distant site, which interferes with the enzymes catalytic function by relying on a mechanism in which information is carried from one region of a large molecule to another region far away from it through subtle structural reorganizations.

These findings highlight the promise of Ebselen as a repurposed drug against SARS-CoV-2.

The study authors

In an exclusive interview for Medical News Today, James Hindley, Ph.D., explained how he and his collaborator Martin Scurr, Ph.D. a research associate at Cardiff Universitys School of Medicine in the United Kingdom are working on a new test that measures a key component of the immune system: T cells.

Hindley, who is the Executive Director at Indoor Biotechnologies in Cardiff, told MNT that most of the existing tests focus on assessing antibodies to determine immunity to SARS-CoV-2.

However, another critical component of our immune response to viruses is the T cell. These also provide memory immune responses and may even be more sensitive than antibodies, said Hindley.

T cells are a type of lymphocyte, or white blood cell, that the bone marrow produces. Before neutralizing antibodies even come into play, different types of T cells have to collaborate to lead to antibody production.

The test we have developed can provide quantitative results measuring the magnitude of an individuals T-cell response to the SARS-CoV-2 virus. We can also run in parallel the same test for other human coronaviruses and viruses, such as influenza. This allows us to establish a persons immune status.

James Hindley, Ph.D.

The researcher went on to explain that the test will be useful for vaccine development; to determine whether a T-cell response to the vaccine has been generated and whether that is adequate to be protective from infection.

We also believe this test will enable public health bodies to perform much wider screenings of the population. [T]his would be carried out by laboratories in conjunction with antibody testing to determine what constitutes protective immunity.

Finally, the researcher also explained how this test is more effective than others.

Where we were innovative was looking at the minimum requirements to perform this test, to get the necessary data to answer the question of whether a person has specific T-cell responses.

By providing just these elements without the added complexity, we made this test much easier to perform in almost any lab.

New research spearheaded by Marcus Buggert, an immunologist at the Karolinska Institutet in Sweden, also has T cells at its heart.

Buggert and his team found that 30 out of 31 people who recovered from a mild SARS-CoV-2 infection had memory T-cell responses to the new virus.

Out of the same sample, 27 had antibodies against the coronavirus. Such findings add to the newly emerging direction in research that uses T cells as an alternative path to COVID-19 immunity.

In the new study, T cell responses were still visible months after a mild infection, sometimes even in the absence of antibodies.

In the absence of a protective vaccine, says Buggert, it is critical to determine if exposed or infected people, especially those with asymptomatic or very mild forms of the disease who likely act inadvertently as the major transmitters, develop robust adaptive immune responses against SARS-CoV-2.

Our findings suggest that the reliance on antibody responses may underestimate the extent of population-level immunity against SARS-CoV-2. The obvious next step is to determine whether robust memory T-cell responses in the absence of detectable antibodies can protect against COVID-19 in the long term.

Marcus Buggert

Finally, an observational study found a class of drugs called interleukin-6 (IL-6) receptor inhibitors to be the most effective for treating severe forms of COVID-19.

In fact, the new study found that these drugs are even more effective than remdesivir or dexamethasone the other two treatments widely heralded as beneficial, based on clinical trial results.

Healthcare professionals typically prescribe IL-6 receptor inhibitors for conditions with an autoimmune component, such as rheumatoid arthritis, to dampen the immune systems excessive response.

IL-6 receptor inhibitors as their name suggests block the receptors of IL-6, which is an immune signaling molecule, or cytokine.

In COVID-19, this action helps calm down the phenomenon known as the cytokine storm, which can lead to potentially fatal outcomes in people with the disease.

In the new paper, for which Dr. Pranay Sinha from the Section of Infectious Diseases at Boston University School of Medicine, MA, was the first author, the researchers explain that the participants who received the 1L-6 inhibitors had considerably higher supplementary oxygen requirements, indicating more advanced disease, than patients in the remdesivir and dexamethasone trials and would have been expected to have a higher mortality rate.

However, the IL-6 inhibitor recipients had a lower mortality rate than patients in the intervention and control groups of those trials.

Furthermore, the mortality rate for the participants who required ICU care was 22.9%. This rate was considerably lower than the published 4550% mortality in other ICU cohorts.

The majority of patients (85.5%) were also discharged alive, which is higher than the reported rate with standard of care (3666%) over a similar time of follow-up. Overall, the authors conclude:

[IL-6 inihitor] use was associated with decreased mortality, decreased rate of intubation, higher likelihood of being discharged alive, and shorter length of stay.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See more here:
Treating COVID-19: Bipolar drug shows promise and other hopeful findings - Medical News Today

Posted in Cell Medicine | Comments Off on Treating COVID-19: Bipolar drug shows promise and other hopeful findings – Medical News Today

New type of taste cell discovered in mice – UB News Center

Posted: August 23, 2020 at 8:57 am

Researchers Kathryn Medler (left), University at Buffalo associate professor of biological sciences, and Debarghya Dutta Banik, a UB PhD graduate who is now a postdoctoral fellow at the Indiana University School of Medicine, pictured in 2019 at UB. Credit: Douglas Levere / University at Buffalo

Multitasking taste cells can sense bitter, sweet, sour and umami stimuli, challenging scientists understanding of how taste buds work

Release Date: August 20, 2020

BUFFALO, N.Y. Some taste cells are multitaskers that can detect bitter, sweet, umami and sour stimuli, a new study finds.

The research challenges conventional notions of how taste works. In the past, it was thought that taste cells were highly selective, capable of discerning only one or two types of the five basic stimuli (only sweet, for instance, or only salty and sour). Though many cells are indeed specialists, the discovery of a subset of cells that can respond to up to four different tastes suggests that taste science is more complex than previously thought.

The study was published on Aug. 13 in the journal PLOS Genetics. The research was done on mice, which have a very similar taste system to humans, says Kathryn Medler, PhD, associate professor of biological sciences in the UB College of Arts and Sciences, who led the study with first author Debarghya Dutta Banik.

This changes the way weve been thinking about how taste cells function and how taste information is collected in a taste bud and sent back to the brain, Medler says. Our data fills in a lot of holes. Other research has suggested that taste cells can be broadly responsive, but we were able to isolate individual taste cells and describe how they work. I cannot definitively state that humans have these broadly responsively taste cells, but based on the high degree of similarity between the mouse and human taste systems, I predict that these cells are very likely present in humans.

Most taste cells selectively respond to a specific stimulus type while broadly responsive cells respond to multiple taste qualities. Credit: Jhanna Flora and Kathryn Medler

It is currently believed that taste cells are very specific about what stimuli they detect. The surprising thing with this new cell population is that individual cells can detect bitter, sweet, umami as well as sour stimuli, says Dutta Banik, PhD, a postdoctoral fellow in anatomy, cell biology and physiology in the Indiana University School of Medicine. Dutta Banik did the research while pursuing his doctorate at UB. It was surprising to know that individual taste cells can respond to so many taste qualities.

What happens when these multitasking cells are silenced?

Researchers Ann-Marie Torregrossa, University at Buffalo assistant professor of psychology, and Kathryn Medler, UB associate professor of biological sciences, pictured in 2019. Credit: Douglas Levere / University at Buffalo

Taste cells are critical to survival: They help us decide whether a food is a good source of nutrients or a potential poison.

Beyond identifying the multitasking taste cells, the new study describes some of their traits. Scientists showed that the cells detect sour stimuli using one signaling pathway, and sweet, bitter and umami stimuli using a different pathway.

Experiments also showed that when broadly responsive taste cells are silenced, mice have trouble tasting sweet, bitter and umami stimuli. This was the case even when the more selective taste cells those that specialize in detecting individual stimuli remained active, says study co-author Ann-Marie Torregrossa, PhD, assistant professor of psychology in the UB College of Arts and Sciences and associate director of the Center for Ingestive Behavior Research.

We did a series of taste tests, says Torregrossa, who led the behavioral aspects of the study. When the animals were missing the function of either the broadly responsive cells or of the traditional taste cells, they responded to sweet, bitter and umami solutions as if they were water. This is very exciting because it suggests they needed both cells to taste the solution normally. When we did the same taste tests with animals that had both cells, they as you would expect licked the sweet solution avidly and avoided the bitter.

Researcher Debarghya Dutta Banik works with an imaging system. In the new study, this set-up was used to locate taste cells through fluorescent microscopy. Dutta Banik, a postdoctoral fellow at the Indiana University School of Medicine, is pictured in 2019 at the University at Buffalo, where he completed his PhD. Credit: Douglas Levere / University at Buffalo

This shows that both of these cell populations are important for sending the taste information to the brain, Dutta Banik says.

The groundbreaking findings highlight how much scientists still have to learn about taste, including how taste buds work and send information to the brain.

Compared to other sensory systems, we know surprisingly little about how taste is coded and processed, Torregrossa says. This study identifies a new population of cells that are contributing to normal taste function, which could be a large piece in the puzzle.

The study's co-authors also included Eric D. Benfey, Amy R. Nelson, Zachary C. Ahart, Barrett T. Kemp and Bailey R. Kemp in the UB Department of Biological Sciences; and Laura E. Martin, Kristen E. Kay and Gregory C. Loney in the UB Department of Psychology. The research received support from the UB North Campus Imaging Facility, which is funded by the U.S. National Science Foundation.

Media Contact Information

Read more here:
New type of taste cell discovered in mice - UB News Center

Posted in Cell Medicine | Comments Off on New type of taste cell discovered in mice – UB News Center

Page 920«..1020..919920921922..930940..»